Asset Details
Do you wish to reserve the book?
Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism
Do you wish to request the book?
Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism
2020
Overview
In recent years, a precision medicine approach, which customizes medical treatments based on patients' individual profiles and incorporates variability in genes, the environment, and lifestyle, has transformed medical care in numerous medical fields, most notably oncology. Applying a similar approach to Parkinson's disease (PD) may promote the development of disease-modifying agents that could help slow progression or possibly even avert disease development in a subset of at-risk individuals. The urgent need for such trials partially stems from the negative results of clinical trials where interventions treat all PD patients as a single homogenous group. Here, we review the current obstacles towards the development of precision interventions in PD. We also review and discuss the clinical trials that target genetic forms of PD, i.e., GBA-associated and LRRK2-associated PD.
Publisher
Elsevier Inc,Springer International Publishing,Springer Nature B.V
Subject
/ ambroxol
/ Biomedical and Life Sciences
/ Central nervous system diseases
/ Clinical Trials as Topic - methods
/ Deep Brain Stimulation - methods
/ Deep Brain Stimulation - trends
/ GBA
/ Genetic Predisposition to Disease - epidemiology
/ Genetic Predisposition to Disease - genetics
/ Humans
/ Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 - genetics
/ LRRK2
/ Parkinsonian Disorders - epidemiology
/ Parkinsonian Disorders - genetics
/ Parkinsonian Disorders - therapy
/ Patients
/ Precision Medicine - methods
/ Review
/ SNCA
